CompletedPhase 4

Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism

China2,416 participantsStarted 2017-05-12

Plain-language summary

This is a randomized, double blind, placebo-controlled, parallel, multicenter research in order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or asymptomatic new cerebral infarction within 10 days. Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential causes of Embolic Stroke of Undetermined Source (ESUS).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. More than or equal to 18 years old and less than 80 years old;
✓. Acute ischemic stroke, brain magnetic resonance imaging showed non lacunar infarction (subcortical infarction less than or equal to 1.5 cm);
✓. Onset within 72 hours;
✓. Patients or their family members are willing to sign the informed consent.

Exclusion criteria

✕. Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
✕. Transient ischemic attack;
✕. Lacunar infarction;
✕. History of acute stroke within 6 months;
✕. Clear diagnosis of other causes of ischemic stroke (arterial dissection, arteritis, vasospasm, etc.);
✕. The acute infarcts lesion more than one-half lobe in size;
✕. Preceding modified Rankin Scale (mRS) score ≥ 2;
✕. Cumulative usage of traditional Chinese medicine which activating blood circulation more than 3 times after onset, including but not limited to: Danhong, Xueshuantong, Xuesaitong, Ginkgo biloba, sodium ozagrel, Salvia miltiorrhiza, ligustrazine, Erigeron breviscapus, etc;

What they're measuring

Symptomatic or Asymptomatic New Cerebral Infarction

Timeframe: 10 days

Trial details

NCT IDNCT03090113

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-03-30

View on ClinicalTrials.gov More Embolic Stroke trials